Drug addiction is a disease originating in the central nervous system that produces compulsive behaviors despite the negative consequences that may result. Major addictive drugs of abuse include components of tobacco, opiates, marijuana, ethanol, cocaine, and derivatives of amphetamines. While the addictive behaviors produced by these substances may be generally similar, the drugs act at different receptor sites in the brain. Recent studies have shown that opioid receptors play a role regulating the addictive behaviors of other receptors that interact with illicit and legal substances of abuse. Opioid receptors are composed of multiple subtypes whose contributions to addictive behaviors are not fully delineated. Moreover, different compounds acting at a single receptor type may produce dissimilar behaviors due to variations in their chemical structures. Thus, both for delineating the biology and signaling ability of each receptor and for developing novel therapies, it would be desirable to identify multiple small molecule ligands that target a given receptor subtype. This entails expanding the chemical space about each of the receptors as variations in receptor conformations due to distinct ligand structures affect receptor signaling behaviors, and consequently physiological responsiveness. Morphine is a prime example of an opioid ligand with distinctive signaling properties. The specific aim of this project is to identify subtype specific small molecule agonists of the human kappa opioid receptor (KOR). These compounds can be optimized to provide the pharmacological means to precisely control the signaling of their specific target receptor subtype. This work thus provides the addiction field both novel research tools and potential therapeutic scaffolds. This is a luminescence assay based off of a kappa opioid cell line and beta-arrestin technology from DiscoveRx. The dose response assay is developed and performed to confirm hits originally identified in the uHTS luminescent, beta-arrestin assay for antagonists of the KOR receptor 1) OPRK1 beta-Arrestin (DiscoveRx) 2) Assay Medium: Opti-MEM Medium supplemented with 1% hiFBS, 1X Pen/Strep/Glu, 125 ug/mL Hygromycin (1/2 recommended), 250 ug/mL Geneticin (1/2 recommended) 3) Growth Medium: MEM supplemented with 10% hiFBS, 1X Pen/Strep/Glu, 125 ug/mL Hygromycin (1/2 recommended), 250 ug/mL Geneticin (1/2 recommended) uHTS protocol: Day 1 1) Harvest cells using Enzyme-Free Dissociation Buffer (Invitrogen Cat#13151-14). Add 500 cells/well in 5 uL of media to each well of a white, 1536 well plate. 2) Spin cells at 500 rpm for 1 min, then wrap plates in Saran Wrap. 3) Incubate overnight at 37C with 5% CO2. Day 2 1) Using a Highres Biosolutions pintool pin 25 nL to wells Columns 1-2 should be DMSO only (- Control), Columns 3-4 should contain Dynorphin A (+ Control). Working concentration = 200 uM, FAC = 1 uM and Columns 5-48  contain test compounds (10uM final in well concentration). 2) Immediately following pintool addition, spin plates at 500 rpm for 1 min, return assay plates to an incubator at 37C 3) Incubate for 1hr and 30 minutes. 4) During test incubation, prepare Detection Reagent Solution from DiscoveRx (1 part Galacton Star: 5 parts Emerald II and 19 parts Cell Assay Buffer) 5) Add 2.5ul of detection reagent solution to each well. 6) Incubate at room temperature for 60 min in the dark 7) Read plates in a Perkin Elmer Envision using a luminescence protocol Dose Response protocol: Day 1 1) Harvest cells using Enzyme-Free Dissociation Buffer (Invitrogen Cat#13151-14). Add 500 cells/well in 5 uL of media to each well of a white, 1536 well plate. 2) Spin cells at 500 rpm for 1 min, then wrap plates in Saran Wrap. 3) Incubate overnight at 37C with 5% CO2. Day 2 1) Using a Labcyte Echo, DMSO and test compounds are transferred to wells. DMSO only is transferred to columns 1-3 and 46-48(Control wells), while varying volumes of test compounds are transferred to columns 4-45 to achieve the desired test concentrations. Test compound wells in the assay plate are back-filled with DMSO to equalize final assay concentrations. 2) Immediately following Echo transfer, 1.0 uL of assay media is added to columns 1-45 and 1.0 uL of assay media containing 6 uM dynorphin A is added to columns 46-48 for a final assay concentration of 1.0 uM. Centrifuge plates at 500 rpm for 1 min immediately following additions. 3) Incubate for 1hr and 30 minutes. 4) During test incubation, prepare Detection Reagent Solution from DiscoveRx (1 part Galacton Star: 5 parts Emerald II and 19 parts Cell Assay Buffer) 5) Add 2.5ul of detection reagent solution to each well. 6) Incubate at room temperature for 60 min in the dark 7) Read plates in a Perkin Elmer Envision using a luminescence protocol
bao:BAO_0001067 "1966" ; # "is primary assay of" -> "1966"
bao:BAO_0001067 "2133" ; # "is primary assay of" -> "2133"
bao:BAO_0001067 "2284" ; # "is primary assay of" -> "2284"
bao:BAO_0001067 "2343" ; # "is primary assay of" -> "2343"
bao:BAO_0001067 "2344" ; # "is primary assay of" -> "2344"
bao:BAO_0001067 "2352" ; # "is primary assay of" -> "2352"
bao:BAO_0001067 "2359" ; # "is primary assay of" -> "2359"
bao:BAO_0001067 "2370" ; # "is primary assay of" -> "2370"
bao:BAO_0001067 "2492" ; # "is primary assay of" -> "2492"
bao:BAO_0001067 "2493" ; # "is primary assay of" -> "2493"
bao:BAO_0001067 "2497" ; # "is primary assay of" -> "2497"
bao:BAO_0001067 "2500" ; # "is primary assay of" -> "2500"
bao:BAO_0001067 "488822" ; # "is primary assay of" -> "488822"
bao:BAO_0001067 "488824" ; # "is primary assay of" -> "488824"
bao:BAO_0001067 "488833" ; # "is primary assay of" -> "488833"
bao:BAO_0001067 "2478" ; # "is primary assay of" -> "2478"
bao:BAO_0001067 "2498" ; # "is primary assay of" -> "2498"
bao:BAO_0000812 "1785" ; # "has summary assay" -> "1785"
bao:BAO_0000812 "1786" ; # "has summary assay" -> "1786"
bao:BAO_0000808 bao:BAO_0000031 ; # "has primary assay" -> "primary assay"
bao:BAO_0000205 bao:BAO_0000219 ; # "has assay format" -> "cell-based format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BA0_0090012 bao:BAO_0000284 ; # "has participant" -> "G protein coupled receptor" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_0200056 ; # "is bioassay type of" -> "beta galactosidase reporter gene assay"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000212 bao:BAO_0000406 ; # "has assay method" -> "protein fragment complementation method"
bao:BAO_0000207 bao:BAO_0000051 ; # "has detection method" -> "chemiluminescence"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"Selective ligands of the kappa opioid receptor, agonists\"" ; # "screening campaign name" -> ""Selective ligands of the kappa opioid receptor, agonists""
bao:BAO_0002853 "uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay" ; # "has assay title" -> "uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay"
bao:BAO_0002854 bao:BAO_0000010 ; # "has bioassay type" -> "functional"
bao:BAO_0002867 bao:BAO_0000516 ; # "has assay footprint" -> "1536 well plate"
bao:BAO_0002863 bao:BAO_0000535 ; # "has concentration throughput" -> "multiple concentration"
bao:BAO_0002833 "90 minute" ; # "has incubation time value" -> "90 minute"
bao:BA0_0090012 "Dynorphin A 1 micromolar" ; # "has participant" -> "Dynorphin A 1 micromolar"
bao:BAO_0000740 bao:BAO_0000080 ; # "has assay control" -> "positive control"
bao:BA0_0090012 bao:BAO_0000118 ; # "has participant" -> "DMSO"
bao:BAO_0000740 bao:BAO_0000079 ; # "has assay control" -> "negative control"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Lawrence Barak" ; # "material entity assay provider" -> "Lawrence Barak" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000373 ; # "has assay phase characteristic" -> "heterogeneous phase"
bao:BAO_0000118 "0.31%" ; # "DMSO" -> "0.31%"
bao:BA0_0090012 "Kappa-type opioid receptor" ; # "has participant" -> "Kappa-type opioid receptor"
bao:BAO_0002004 <http://purl.obolibrary.org/obo/CLO_0009454> ; # "has cell line" -> "U-2 OS cell"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "P41145" ; # "uniprot ID" -> "P41145"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "10% fetal bovine serum" ; # "material entity culture serum" -> "10% fetal bovine serum" || bao:BAO_0003102 bao:BAO_0002596 ; # "has role" -> "culture serum"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "\"MEM with 10% hiFBS, 1X Pen/Strep/Glu, 125 microg/ml Hygromycin, 250 microg/ml Geneticin\"" ; # "material entity culture medium" -> ""MEM with 10% hiFBS, 1X Pen/Strep/Glu, 125 microg/ml Hygromycin, 250 microg/ml Geneticin"" || bao:BAO_0003102 bao:BAO_0000114 ; # "has role" -> "culture medium"
bao:BAO_0002922 "\"Opti-MEM with 1% hiFBS, 1X Pen/Strep/Glu, 125 microg/ml Hygromycin, 250 microg/ml Geneticin\"" ; # "has assay medium" -> ""Opti-MEM with 1% hiFBS, 1X Pen/Strep/Glu, 125 microg/ml Hygromycin, 250 microg/ml Geneticin""
bao:BAO_0002922 bao:BAO_0000596 ; # "has assay medium" -> "assay medium"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1% fetal bovine serum" ; # "material entity assay serum" -> "1% fetal bovine serum"
bao:BAO_0002923 bao:BAO_0002597 ; # "has assay serum" -> "assay serum"
bao:BAO_0000212 bao:BAO_0000246 ; # "has assay method" -> "stable transfection"
bao:BAO_0000550 "Expressing ProLink/Enzyme Donor (PK)-tagged kappa opioid receptor and the Enzyme Activator (EA)-tagged ?-Arrestin fusion proteins" ; # "DNA construct" -> "Expressing ProLink/Enzyme Donor (PK)-tagged kappa opioid receptor and the Enzyme Activator (EA)-tagged ?-Arrestin fusion proteins"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BA0_0090012 bao:BAO_0000750 ; # "has participant" -> "Beta-galactosidase"
bao:BAO_0002000 bao:BAO_0002001 ; # "has measured entity" -> "measured entity"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BAO_0000308 bao:BAO_0000988 ; # "has assay kit" -> "PathHunter Beta-Arrestin Assay"
bao:BAO_0000308 bao:BAO_0000248 ; # "has assay kit" -> "assay Kit"
bao:BAO_0000737 bao:BAO_0000893 ; # "has manufacturer" -> "DiscoveRx" || bao:BAO_0003102 bao:BAO_0002626 ; # "has role" -> "biologics and screening manufacturer"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0000701 ; # "uses detection instrument" -> "EnVision Multilabel Reader"
bao:BAO_0000737 bao:BAO_0000297 ; # "has manufacturer" -> "Perkin Elmer" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000188 ; # "has endpoint" -> "EC50"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "2" ; # "PubChem TID" -> "2"
bao:BAO_0000196 bao:BAO_0000087 ; # "has mode of action" -> "activation"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "mp" ; # "Annotated by" -> "mp"
